BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced...

Keywords

GemcitabineMedicineSorafenibPlaceboPancreatic cancerInternal medicineOncologyDouble blindDeoxycytidineCancerHepatocellular carcinomaPathology

Affiliated Institutions

Related Publications

Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

Elizabeth Poplin , Yang Feng , Jordan Berlin +9 more

Purpose Single-agent gemcitabine (GEM) is standard treatment of metastatic pancreatic cancer. Fixed-dose rate (FDR) GEM and GEM plus oxaliplatin have shown promise in early clin...

2009 Journal of Clinical Oncology 423 citations

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Ghassan K. Abou‐Alfa , Richard Létourneau , Graydon Harker +8 more

Purpose Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic c...

2006 Journal of Clinical Oncology 277 citations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore , David Goldstein , John Hamm +14 more

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic ...

2007 Journal of Clinical Oncology 3833 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Publication Info

Year: 2012
Type: article
Volume: 23
Issue: 11
Pages: 2799-2805
Citations: 211
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

211

OpenAlex

Influential

180

CrossRef

Cite This

APA Style

                            
                                
                                    Anthony Gonçalvès, 
                                
                                    Marine Gilabert, 
                                
                                    E. François
                                
                                et al.
                            
                            (2012). 
                            BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. 
                            Annals of Oncology
                            , 23
                            (11)
                            , 2799-2805.
                            https://doi.org/10.1093/annonc/mds135
                        

Identifiers

DOI: 10.1093/annonc/mds135
PMID: 32018731

Data Quality

Data completeness: 68%